SOLVO Biotechnology and Hepregen Execute Co-Marketing Agreement
News Jun 24, 2015
SOLVO Biotechnology and Hepregen Corporation have announced, at the 13th European Meeting of the International Society for the Study of Xenobiotics ("ISSX"), a co-marketing agreement between the companies. This agreement provides for the European marketing of Hepregen's human, monkey, rat and dog application-directed HepatoPac® and HepatoMuneT kits, which are used for liver metabolite analysis, transport studies and predictive and mechanistic toxicology studies.
These kits contain human or animal hepatocytes (liver cells) in Hepregen's proprietary micro-patterned, co-culture microtiter tissue culture plates. This agreement provides SOLVO with the opportunity to make services available to its customers using these Hepregen products as well as HepatoPac® B-CLEAR® products co-developed by Hepregen and Qualyst Transporter Solutions.
"Hepregen's technology is a welcome addition to our world-recognized portfolio of products and services associated with transporter protein analysis", said Erno Duda, SOLVO's chief executive officer. "As the transporter field matures, we see a growing need for physiologically relevant systems in addition to the established transfected models. Moreover, adding Hepregen's portfolio to ours provides us with an opportunity to broaden our offerings to customers into the important areas of drug metabolism and safety testing. Our partnership with Hepregen enhances SOLVO's ability to grow as a biotechnology enterprise."
Dr. Vincent Zurawski, Hepregen's president and chief executive, stated, "This marketing partnership represents another step in Hepregen's unceasing effort to make our application-directed products and associated services available to customers around the world," adding, "SOLVO's exceptional European sales capability is expected to dramatically augment our already growing European sales effort."
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Synaptic Proteins May Be Starting Point for Dementia TreatmentNews
A new study has identified key proteins, located at the brain's synaptic connections, which may be viable targets for dementia treatment.READ MORE